Cancer facts & figures 2012. Atlanta: American Cancer Society, 2012. [http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf]
Wang T, Nelson RA, Bogardus A, Grannis FW: Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival?. Cancer. 2010, 116: 1518-1525. 10.1002/cncr.24871.
Article
PubMed
Google Scholar
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002, 346: 92-98. 10.1056/NEJMoa011954.
Article
CAS
PubMed
Google Scholar
Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Song Y, Shi Y: Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2013, 69: 151-159. 10.1007/s00228-012-1333-3.
Article
CAS
PubMed
Google Scholar
Ellis PM, Al-Saleh K: Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol. 2012, 84: 47-58. 10.1016/j.critrevonc.2012.02.004.
Article
PubMed
Google Scholar
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355: 2542-2550. 10.1056/NEJMoa061884.
Article
CAS
PubMed
Google Scholar
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O’Connor P, Shalinsky DR, Bender SL: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008, 14: 7272-7283. 10.1158/1078-0432.CCR-08-0652.
Article
CAS
PubMed
Google Scholar
Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J: Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009, 27: 3836-3841. 10.1200/JCO.2008.20.8355.
Article
PubMed
Google Scholar
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB: Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer. 2012, 107: 1277-1285. 10.1038/bjc.2012.406.
Article
CAS
PubMed
PubMed Central
Google Scholar
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008, 26: 3543-3551. 10.1200/JCO.2007.15.0375.
Article
CAS
PubMed
Google Scholar
Tortorici MA, Iglesias L, Kozloff MF, Pithavala YK, Ingrosso A, Belani CP: Pharmacokinetic (PK) analysis of coadministration of axitinib and pemetrexed/cisplatin (pem/cis) in patients with non–small cell lung cancer (NSCLC) [abstract PI-69]. Clin Pharmacol Ther. 2012, 91 (Suppl 1): S33-
Google Scholar
Cleeland CS: The M. D. Anderson Symptom Inventory User Guide [Draft]. Houston, Texas, University of Texas M. D. Anderson Cancer Center. 2010, Houston, TX: The University of Texas MD Anderson Cancer Center, [http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/MDASI_userguide.pdf]
Google Scholar
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O’Byrne KJ, Gatzemeier U: Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer. 2012, 77: 376-382. 10.1016/j.lungcan.2012.03.010.
Article
CAS
PubMed
Google Scholar
Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, de Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010, 28: 1835-1842. 10.1200/JCO.2009.26.1321.
Article
CAS
PubMed
Google Scholar
Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR: International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced non-squamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012, 30: 2829-2836. 10.1200/JCO.2011.41.4987.
Article
CAS
PubMed
Google Scholar
Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A, NSCLC [non-small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group: Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, non-squamous non-small-cell lung cancer. J Clin Oncol. 2012, 30: 3084-3092. 10.1200/JCO.2011.39.7646.
Article
CAS
PubMed
Google Scholar
Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007, 13: 3942-3950. 10.1158/1078-0432.CCR-07-0278.
Article
CAS
PubMed
Google Scholar
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK: Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011, 91: 1071-1121. 10.1152/physrev.00038.2010.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ma J, Waxman DJ: Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther. 2008, 7: 79-89.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hoh C, Infante JR, Burris HA, Tarazi JC, Kim S, Rosbrook B, Reid TR: Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): implications for cytotoxic chemotherapy combinations [abstract 3591]. J Clin Oncol. 2011, 29 (Suppl): 15s-
Google Scholar
Jeraj R, Liu G, Simoncic U, Vanderhoek M, Perlman S, Alberti DB, Harrison MR, Wilding G: Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI [abstract 3050]. J Clin Oncol. 2010, 28 (Suppl): 15s-
Google Scholar
Joyce JA: Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005, 7: 513-520. 10.1016/j.ccr.2005.05.024.
Article
CAS
PubMed
Google Scholar
Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH: Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010, 28: 949-954. 10.1200/JCO.2009.25.4482.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O: Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011, 17: 3841-3849. 10.1158/1078-0432.CCR-10-2806.
Article
CAS
PubMed
Google Scholar
Mok TSK, Paz-Ares L, Wu Y-L, Novello S, Juhasz E, Aren O, Sun Y, Hirsh V, Smit EF, Lathia C, Ong TJ, Pena C: Association between tumor EGFR and KRas mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: subanalysis of the phase III MISSION trial [abstract LBA9_PR]. Ann Oncol. 2012, 23 (Suppl 9): ixe1-
Article
Google Scholar
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500. 10.1126/science.1099314.
Article
CAS
PubMed
Google Scholar
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, Klingelschmitt G, Klughammer B, Giaccone G, SATURN investigators: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11: 521-529. 10.1016/S1470-2045(10)70112-1.
Article
CAS
PubMed
Google Scholar
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010, 363: 1693-1703. 10.1056/NEJMoa1006448.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH: Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol Ther. 2011, 12: 458-465. 10.4161/cbt.12.5.16303.
Article
CAS
PubMed
Google Scholar
Henderson YC, Ahn SH, Kang Y, Clayman GL: Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res. 2008, 14: 4908-4914. 10.1158/1078-0432.CCR-07-1772.
Article
CAS
PubMed
PubMed Central
Google Scholar